Cancer Research Cancer Research Funding Available  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 1732-1740, April 15, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cuthbert, J. A.
Right arrow Articles by Lipsky, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuthbert, J. A.
Right arrow Articles by Lipsky, P. E.

Suppression of the Proliferation of Ras-transformed Cells by Fluoromevalonate, an Inhibitor of Mevalonate Metabolism1

Jennifer A. Cuthbert2 and Peter E. Lipsky

Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235-8887

Mevalonate is the precursor of a number of different products potentially required for the growth of cells, including the prenylated oncoprotein Ras. To determine whether inhibition of mevalonate metabolism would selectively block proliferation of Ras-transformed cells, 6-fluoromevalonate (Fmev), an inhibitor of diphosphomevalonate decarboxylase, was used to block the synthesis of prenyl-derived lipids and prenylated proteins in interleukin-3 (IL-3)-dependent FDC-P1 cells (control FDC-P1 cells) and FDC-P1 cells transformed with oncogenic Ras (RasDC cells) that proliferated in the absence of IL-3. Fmev completely inhibited synthesis of prenyl-derived lipids and prenylated proteins and blocked proliferation of FDC-P1 and RasDC cells. Restoration of the proliferation of Fmev-blocked FDC-P1 cells required both an exogenous source of cholesterol and prevention of the accumulation of mevalonate and the mevalonate phosphates with lovastatin. In contrast, ongoing IL-3-independent proliferation of Fmev-blocked RasDC cells was not completely restored by providing exogenous cholesterol and preventing the accumulation of inhibitory mevalonate product(s). However, these cells proliferated when cultures were supplemented with IL-3 together with exogenous cholesterol and lovastatin, implying that Fmev had prevented Ras-dependent, IL-3-independent growth. Fmev markedly diminished total cellular Ras in RasDC cells. In contrast, lovastatin depleted membrane-associated Ras and increased cytosolic Ras but did not diminish total cellular Ras. These data indicate that Fmev depletes total cellular Ras and specifically inhibits the autonomous growth of Ras-transformed cells.

1 This work was supported by Grant CN-108 from the American Cancer Society and Public Health Service Grant AI-17653 from the NIH.

2 To whom requests for reprints should be addressed, at Liver Unit, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-8887.

Received 12/27/94. Accepted 2/13/95.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. Oberdoerster, M. Guizzetti, and L. G. Costa
Effect of Phenylalanine and Its Metabolites on the Proliferation and Viability of Neuronal and Astroglial Cells: Possible Relevance in Maternal Phenylketonuria
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 295 - 301.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
R. S. J. Makar, P. E. Lipsky, and J. A. Cuthbert
Sterol-independent, sterol response element-dependent, regulation of low density lipoprotein receptor gene expression
J. Lipid Res., August 1, 1998; 39(8): 1647 - 1654.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. M. Forman, B. Ruan, J. Chen, G. J. Schroepfer Jr., and R. M. Evans
The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism
PNAS, September 30, 1997; 94(20): 10588 - 10593.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
L. He, H. Mo, S. Hadisusilo, A. A. Qureshi, and C. E. Elson
Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo
J. Nutr., May 1, 1997; 127(5): 668 - 674.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. J. Toth and L. Huwyler
Molecular Cloning and Expression of the cDNAs Encoding Human and Yeast Mevalonate Pyrophosphate Decarboxylase
J. Biol. Chem., April 5, 1996; 271(14): 7895 - 7898.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.